Company
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 3 of 4
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
The FTSE 100 closed out Thursday up around 67 points at 7,555.
Archive
The big mover, up 64%, was Advanced Oncotherapy, which is building a next-generation proton therapy system
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Peter Allen will not be going back to the Future board room after February's AGM
The better-than-expected outcome reflects a trebling in the share price of Immupharma
Not much happening among the blue-chips but Image Scan and Future were among the big movers in the small caps sector
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"We continue to believe that in order for an organisation to build and sustain a business-critical innovation ethos and competency, technology and consultancy need to be implemented in a joined-up way," said Imaginatik
Lupuzor is currently undergoing a phase III clinical trial 200 in patients in the US, Europe and Mauritius
There has been no news flow from FTSE 100 companies to speak of today
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"I am particularly pleased to confirm funds released through the hedging facility will not carry any geographical restrictions. This means we will be able to deploy capital across our entire portfolio," said CEO, Matt Lofgran
Decision to start to manufacture commercial batches was taken in anticipation of the trial's successful outcome and to exploit 'fast track' status'
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Safestyle UK has more cash than it needs at present
We’ll know how effective Lupuzor is when the top line data is shared with the market in the first quarter of next year
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
Archive
A summary of some of the small cap stories on the Proactive newswire
Some of the main risers and fallers in London at 3.45pm...
Lupuzor, for the autoimmune disease lupus, is undergoing phase III clinical trials.
After a gloomy morning for the pound, it started to build some momentum. FTSE 100 finished at 7,543
Archive
Day ahead: RBS likely to avert High Court trial; finals from FirstGroup, Johnson Matthey and ImmuPharma
Archive
Week ahead; IG Group, Ryanair, Johnson Matthey, Non-Farm Payrolls,
Archive
A glance at some of the stories on the Proactive newswire...
A look at some of the biggest London-listed risers and fallers today
The trial runs for twelve months and 28 patients have now received the full dosage and 166 (80%) six months' worth
The UK blue chip index closed down 18.56 points at 7,503
L&G upped its stake in the recent £4.1mln fundraising, and now holds a 3.5% stake in ImmuPharma
Some of the largest rises and falls in London at 10.00am: SynairGen, BOS Global, Angus Energy
The life sciences group said the accelerated book-build offering saw around 7.884 mln new shares placed at 52p each, a modest discount to last night’s closing share price
FTSE 100 stocks ended higher on Friday, led by telecoms behemoth BT after confirming it would separate Openreach
Archive
A glance at some of the stories on the Proactive newswire today.
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
In all 293 patients were screened to take part in the study and 200 were accepted.
2017 could be a big year for these four lesser-known junior drug developers
Archive
A glance at some of the stories on the Proactive newswire today
It has delivered on its plan to have 200 sufferers of the life-threatening auto-immune disease taking part in the study by the end of the year.
FTSE 100 stocks ended higher on Thursday after pulling away from flat positions at midsession while small-caps helped 40% of London’s stocks to gain – one of their best performances this year - but falling prices for copper, zinc and nickel
Archive
A round-up of some of today's broker commentary
Immupharma among the small cap pharmas in focus on Wednesday, alongside Futura Medical, Horizon Discovery Group, and Summit Therapeutics.
One analyst thinks the drug discoverer could add at least another £1 to its share price
L&G has a 3.43% stake after participating in the drug developer's well-supported share placing earlier this year
Also in the news, Hurricane Energy has started drilling on its latest well in the North Sea, while Premier African hits ‘significant’ lithium grades in Zimbabwe
Immupharma said that this cash would be used on lupus treatment Lupuzor
Serial small cap promoter David Lenigas gets behind Premier African, Falcon Oil & Gas reports “excellent gas shows”, and slot machine software group Quixant hits the jackpot with half-year results.
Daily round up of the day's news headlines from Proactive Investors.
The request to open a new site came directly from the government following a visit to the island nation by the drug’s inventor, professor Sylviane Muller.
Archive
The bank has picked out several banking and financial stocks that it likes the look of, although Barclays has had its own stock downgraded by UBS
A mixed news bag but small cap miners appeared to be out in force
It is a potential blockbuster, said the broker, which targets 171p for the share.
Drug company said it had started dosing Lupus sufferers with Lupuzor
Archive
Take Aim. London’s growth stocks have been immune to the negativity dogging the market for blue-chip shares.
Up more 67% in last five trading sessions it has been on the rampage since it was revealed that Alto Invest had taken its stake to 4.15%.
The FTSE 100 surrendered all of May's gains to close 10 points down on the month
The FTSE 100 Index trod water as traders shrugged off mixed economic data from the continent
ITM Power announced that London's first hydrogen refuelling station is to open next week, Westminster Group awaits the arrival of the Sierra Princess and Deltex Medical reconfigures its probe tip.
"ImmuPharma is focused on ensuring the successful development of the late stage clinical development of Lupuzor through its pivotal phase III trial,” chairman Tim McCarthy told investors.
As if the UK retail sector hadn't had enough coverage last week, it's now the turn of Sainsbury's....
A trio of AIM companies are putting potential new drugs through phase three trials
Recruiting patients in Europe has now begun for the pivotal phase III trial of Lupuzor, the firm said.
Archive
Horse Hill off to the races, Forbidden technologies extends contract and PureCircle doubles earnings.
Shares in ImmuPharma nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.
Drug discovery firm ImmuPharma has raised £7.7mln from the previously announced fundraise and is due to receive a further £0.7mln from advance assurances.
Archive
Everything appears to being going to plan for 88 Energy in Alaska...
In all clinical trials will take place across 45 locations – 10 in America, the rest in Europe.
The company will use cash to fund its share of costs of developing Lupuzor, the potential blockbuster drug for autoimmune disease Lupus, which is undergoing phase III clinical trials.
Investments and investor services
Weatherly International, Motif Bio and 88 energy also had news out on Tuesday
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
ImmuPharma was host to 70 investigators and senior coordinators from the US and Europe who will be involved in the pivotal phase-III trial of Lupuzor...
Below are the main news-driven share price movements at 4pm
Investments and investor services
The FTSE100 ended the day almost 15 points lower to 6,223.
Investments and investor services
Sunrise Resources, Optibiotix Health and ITM Power also had news out
Investments and investor services
Below are the main news-driven share price movements at 4pm.
Archive
Pride of place goes to Plethora Solutions, after Jim Mellon's Regent Pacific offered to take it over.
The study, being carried out with the help of clinical research firm Simbec-Orion, will take place at 45 different sites – 10 in the US, 35 in Europe.
Investments and investor services
Pharma companies and energy firms were in the news today...
Dr Ajay Agrawal is to step down with immediate effect
Archive
If you're a fan of interim results statements, today was dedicated to you.